TMS Co

TMS Co Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of TMS Co (4891.T) as of Nov 3, 2026 is 39.86. In the previous year, Days Inventory Outstanding (DIO) was 2,627.21 — a change of -98.48% (lower).

Days Inventory Outstanding

39.86

YoY

-98.48%

Last updated:

Days Inventory Outstanding (DIO) of TMS Co is 2025 39.86 . Days Inventory Outstanding (DIO) of TMS Co was 2024 2,627.21 . It decreases by -98.48% lower compared to the previous year.

The TMS Co Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2021
3,762.74 JPY
Jan 1, 2022
90.37 JPY
Jan 1, 2023
12.34 JPY
Jan 1, 2024
2,627.21 JPY
Jan 1, 2025
39.86 JPY
The TMS Co Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
39.86-98.48%
2,627.21+21,190.12%
12.34-86.34%
90.37-97.60%
3,762.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Days Inventory Outstanding (DIO) of TMS Co is 39.86 in 2025.

Days Inventory Outstanding (DIO) of TMS Co changed from 2,627.21 to 39.86, representing a -98.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) TMS Co since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s TMS Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TMS Co

All Key Metrics — TMS Co